Evogene Ltd
NASDAQ:EVGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Evogene Ltd
Total Assets
Evogene Ltd
Total Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Evogene Ltd
NASDAQ:EVGN
|
Total Assets
$20m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-16%
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Total Assets
$378.7m
|
CAGR 3-Years
6%
|
CAGR 5-Years
12%
|
CAGR 10-Years
14%
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Total Assets
$20.9m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-1%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Total Assets
$200.5m
|
CAGR 3-Years
14%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Total Assets
$17.4m
|
CAGR 3-Years
4%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Total Assets
$30.6m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-6%
|
|
Evogene Ltd
Glance View
Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
See Also
What is Evogene Ltd's Total Assets?
Total Assets
20m
USD
Based on the financial report for Dec 31, 2025, Evogene Ltd's Total Assets amounts to 20m USD.
What is Evogene Ltd's Total Assets growth rate?
Total Assets CAGR 10Y
-16%
Over the last year, the Total Assets growth was -50%. The average annual Total Assets growth rates for Evogene Ltd have been -29% over the past three years , -23% over the past five years , and -16% over the past ten years .
